Cargando…

Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson’s Disease: An Open-Label Prospective Study

Patients with Parkinson’s disease (PD) can improve some non-motor symptoms (NMS) after starting treatment with opicapone. The aim of this study was to analyze the effectiveness of opicapone on global NMS burden in PD. OPEN-PD (Opicapone Effectiveness on Non-motor symptoms in Parkinson’s Disease) is...

Descripción completa

Detalles Bibliográficos
Autores principales: Santos García, Diego, Fernández Pajarín, Gustavo, Oropesa-Ruiz, Juan Manuel, Escamilla Sevilla, Francisco, Rahim López, Raúl Rashid Abdul, Muñoz Enríquez, José Guillermo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945982/
https://www.ncbi.nlm.nih.gov/pubmed/35326339
http://dx.doi.org/10.3390/brainsci12030383
_version_ 1784674084741709824
author Santos García, Diego
Fernández Pajarín, Gustavo
Oropesa-Ruiz, Juan Manuel
Escamilla Sevilla, Francisco
Rahim López, Raúl Rashid Abdul
Muñoz Enríquez, José Guillermo
author_facet Santos García, Diego
Fernández Pajarín, Gustavo
Oropesa-Ruiz, Juan Manuel
Escamilla Sevilla, Francisco
Rahim López, Raúl Rashid Abdul
Muñoz Enríquez, José Guillermo
author_sort Santos García, Diego
collection PubMed
description Patients with Parkinson’s disease (PD) can improve some non-motor symptoms (NMS) after starting treatment with opicapone. The aim of this study was to analyze the effectiveness of opicapone on global NMS burden in PD. OPEN-PD (Opicapone Effectiveness on Non-motor symptoms in Parkinson’s Disease) is a prospective open-label single-arm study conducted in 5 centers from Spain. The primary efficacy outcome was the change from baseline (V0) to the end of the observational period (6 months ± 30 days) (V2) in the Non-Motor Symptoms Scale (NMSS) total score. Different scales were used for analyzing the change in motor, NMS, quality of life (QoL), and disability. Thirty-three patients were included between JUL/2019 and JUN/2021 (age 63.3 ± 7.91; 60.6% males; 7.48 ± 4.22 years from symptoms onset). At 6 months, 30 patients completed the follow-up (90.9%). The NMSS total score was reduced by 27.3% (from 71.67 ± 37.12 at V0 to 52.1 ± 34.76 at V2; Cohen’s effect size = −0.97; p = 0.002). By domains, improvement was observed in sleep/fatigue (−40.1%; p < 0.0001), mood/apathy (−46.6%; p = 0.001), gastrointestinal symptoms (−20.7%; p = 0.029), and miscellaneous (−44.94%; p = 0.021). QoL also improved with a 18.4% reduction in the 39-item Parkinson’s Disease Quality of Life Questionnaire Summary Index (from 26.67 ± 17.61 at V0 to 21.75 ± 14.9 at V2; p = 0.001). A total of 13 adverse events in 11 patients (33.3%) were reported, 1 of which was severe (not related to opicapone). Dyskinesias and nausea were the most frequent (6.1%). Opicapone is well tolerated and improves global NMS burden and QoL in PD patients at 6 months.
format Online
Article
Text
id pubmed-8945982
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89459822022-03-25 Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson’s Disease: An Open-Label Prospective Study Santos García, Diego Fernández Pajarín, Gustavo Oropesa-Ruiz, Juan Manuel Escamilla Sevilla, Francisco Rahim López, Raúl Rashid Abdul Muñoz Enríquez, José Guillermo Brain Sci Article Patients with Parkinson’s disease (PD) can improve some non-motor symptoms (NMS) after starting treatment with opicapone. The aim of this study was to analyze the effectiveness of opicapone on global NMS burden in PD. OPEN-PD (Opicapone Effectiveness on Non-motor symptoms in Parkinson’s Disease) is a prospective open-label single-arm study conducted in 5 centers from Spain. The primary efficacy outcome was the change from baseline (V0) to the end of the observational period (6 months ± 30 days) (V2) in the Non-Motor Symptoms Scale (NMSS) total score. Different scales were used for analyzing the change in motor, NMS, quality of life (QoL), and disability. Thirty-three patients were included between JUL/2019 and JUN/2021 (age 63.3 ± 7.91; 60.6% males; 7.48 ± 4.22 years from symptoms onset). At 6 months, 30 patients completed the follow-up (90.9%). The NMSS total score was reduced by 27.3% (from 71.67 ± 37.12 at V0 to 52.1 ± 34.76 at V2; Cohen’s effect size = −0.97; p = 0.002). By domains, improvement was observed in sleep/fatigue (−40.1%; p < 0.0001), mood/apathy (−46.6%; p = 0.001), gastrointestinal symptoms (−20.7%; p = 0.029), and miscellaneous (−44.94%; p = 0.021). QoL also improved with a 18.4% reduction in the 39-item Parkinson’s Disease Quality of Life Questionnaire Summary Index (from 26.67 ± 17.61 at V0 to 21.75 ± 14.9 at V2; p = 0.001). A total of 13 adverse events in 11 patients (33.3%) were reported, 1 of which was severe (not related to opicapone). Dyskinesias and nausea were the most frequent (6.1%). Opicapone is well tolerated and improves global NMS burden and QoL in PD patients at 6 months. MDPI 2022-03-12 /pmc/articles/PMC8945982/ /pubmed/35326339 http://dx.doi.org/10.3390/brainsci12030383 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Santos García, Diego
Fernández Pajarín, Gustavo
Oropesa-Ruiz, Juan Manuel
Escamilla Sevilla, Francisco
Rahim López, Raúl Rashid Abdul
Muñoz Enríquez, José Guillermo
Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson’s Disease: An Open-Label Prospective Study
title Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson’s Disease: An Open-Label Prospective Study
title_full Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson’s Disease: An Open-Label Prospective Study
title_fullStr Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson’s Disease: An Open-Label Prospective Study
title_full_unstemmed Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson’s Disease: An Open-Label Prospective Study
title_short Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson’s Disease: An Open-Label Prospective Study
title_sort opicapone improves global non-motor symptoms burden in parkinson’s disease: an open-label prospective study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945982/
https://www.ncbi.nlm.nih.gov/pubmed/35326339
http://dx.doi.org/10.3390/brainsci12030383
work_keys_str_mv AT santosgarciadiego opicaponeimprovesglobalnonmotorsymptomsburdeninparkinsonsdiseaseanopenlabelprospectivestudy
AT fernandezpajaringustavo opicaponeimprovesglobalnonmotorsymptomsburdeninparkinsonsdiseaseanopenlabelprospectivestudy
AT oropesaruizjuanmanuel opicaponeimprovesglobalnonmotorsymptomsburdeninparkinsonsdiseaseanopenlabelprospectivestudy
AT escamillasevillafrancisco opicaponeimprovesglobalnonmotorsymptomsburdeninparkinsonsdiseaseanopenlabelprospectivestudy
AT rahimlopezraulrashidabdul opicaponeimprovesglobalnonmotorsymptomsburdeninparkinsonsdiseaseanopenlabelprospectivestudy
AT munozenriquezjoseguillermo opicaponeimprovesglobalnonmotorsymptomsburdeninparkinsonsdiseaseanopenlabelprospectivestudy